Forward Pharma A S (FWPAY)

2.800 +0.000 (+0.00%)
Close USD Disclaimer

Forward Pharma A S Company Profile

Equity Type
Forward Pharma A/S is a Denmark-based biopharmaceutical company, that commenced development in 2005 of a formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.
Contact Information
Copenhagen K Copenhagen,1100 Denmark
45 33 44 42 42
Top Executives
Ulrich Mrowietz 0 0000 Scientific Advisor
Torsten Goesch 62 2006 Director
Kristian Reich 0 0000 Scientific Advisor
Florian Schonharting 52 2005 Co-Founder & Chairman of the Board
Duncan Moore 62 2016 Independent Non-Executive Director
Jerry S. Wolinsky 0 0000 Scientific Advisor
Per Soelberg Sørensen 0 0000 Scientific Advisor
Grant Hellier Lawrence 59 2015 Independent Director
Fred D. Lublin 0 0000 Scientific Advisor
Giancarlo Comi 0 0000 Scientific Advisor
Jakob Mosegaard Larsen 48 2015 Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles